Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LOPID U.S. VOLUME UP 85% IN FIRST QUARTER AS WARNER-LAMBERT REPORTS 14% INCREASE IN ETHICAL DRUG SALES WORLDWIDE; DIVESTITURE OF THREE UNITS DROPS OVERALL SALES

Executive Summary

Warner-Lambert U.S. sales of its lipid-regulating drug Lopid increased 85% in the first quarter of 1986, the firm said in reporting first quarter results. "New Rxs for Lopid reached an all-time high, reflecting the medical profession's growing awareness of the role of blood lipids in the development of atherosclerosis," the company stated in an April 29 release. The product is now marketed in 27 countries. Lopid was just one of Warner-Lambert's bright spots for the three months ended March 31. Sales of ERYC erythromycin were up 25% in the U.S., "aided by a high incidence of respiratory infection," the company said. In addition, U.S. volume of the nonsteroidal anti-inflammatory drug Meclomen was up 35%. "The U.S. pharmaceutical business also benefited from higher sales of the epilepsy drug Dilantin, as well as the introduction in the first quarter of Doryx, a patented form of the antibiotic doxycycline," Warner-Lambert added. "Sales of multisource products also contributed to the gain." Worldwide sales of ethical pharmaceuticals increased 14% over the first quarter of 1985, according to the release. Overall, Warner-Lambert reported a 6% decline in sales volume to $747 mil. during the 13-week period. Excluding the three businesses now being divested -- Deseret, Reichert and IMED -- sales would have increased 9%, the company said. Net income rose almost 9% to $65.1 mil. Chairman Joseph Williams attributed the earnings gain to higher sales of all continuing businesses and lower administrative costs. On the OTC side, Warner-Lambert reported a 4% increase in worldwide sales. "U.S. sales were buoyed by several new products and major line extensions," the firm said. "Benadryl anti-histamine, introduced last year as an OTC allergy medication, has attained market leadership, stimulated by the introduction of two additional product formulations." chart omitted.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel